NASDAQ:LHDX - Lucira Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.15
▲ +0.1 (4.88%)

This chart shows the closing price for LHDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lucira Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LHDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LHDX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Lucira Health in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.15.

This chart shows the closing price for LHDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Lucira Health. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/17/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2022Lifesci CapitalUpgradeMarket Perform ➝ OutperformLow
8/13/2021Lifesci CapitalDowngradeOutperform ➝ Market PerformMedium
5/10/2021William BlairReiterated RatingOutperform ➝ Market PerformN/A
5/4/2021William BlairDowngradeOutperform ➝ Market PerformHigh
4/19/2021Bank of AmericaReiterated RatingBuy ➝ Underperform$9.00N/A
4/13/2021Bank of AmericaDowngradeBuy ➝ Underperform$9.00High
3/2/2021Lifesci CapitalReiterated RatingOutperformHigh
3/2/2021William BlairInitiated CoverageOutperformHigh
3/2/2021Bank of AmericaInitiated CoverageNeutral$22.00High
(Data available from 5/17/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/19/2021
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/18/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/18/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/17/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/16/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/18/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2022
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
5/17/2022

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Lucira Health logo
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $2.15
Low: $2.00
High: $2.15

50 Day Range

MA: $3.26
Low: $2.05
High: $3.99

52 Week Range

Now: $2.15
Low: $1.98
High: $11.10

Volume

1,739 shs

Average Volume

63,043 shs

Market Capitalization

$85.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Lucira Health?

The following sell-side analysts have issued stock ratings on Lucira Health in the last year: Lifesci Capital, and Zacks Investment Research.
View the latest analyst ratings for LHDX.

What is the current price target for Lucira Health?

0 Wall Street analysts have set twelve-month price targets for Lucira Health in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Lucira Health in the next year.
View the latest price targets for LHDX.

What is the current consensus analyst rating for Lucira Health?

Lucira Health currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LHDX will outperform the market and that investors should add to their positions of Lucira Health.
View the latest ratings for LHDX.

How do I contact Lucira Health's investor relations team?

Lucira Health's physical mailing address is 1412 62ND STREET, EMERYVILLE CA, 94608. The company's listed phone number is 510-350-8071. The official website for Lucira Health is www.lucirahealth.com. Learn More about contacing Lucira Health investor relations.